No Data
No Data
Retail Investors Invested in Berry Genomics Co.,Ltd (SZSE:000710) Copped the Brunt of Last Week's CN¥371m Market Cap Decline
Berry Genomics: Summary of Half-Year Report in 2024.
Berry Genomics: Half-year report for the year 2024.
Berry Genomics (000710.SZ): The net income in the first half of the year was 9.2628 million yuan, turning the loss around from the same period last year.
Galontex reported its interim report for the first half of 2024 on August 22, with operating revenue of 0.552 billion yuan, a 1.59% year-on-year decrease; net income attributable to shareholders of the listed company was 9.2628 million yuan, turning losses into profits year-on-year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 9.48996 million yuan; basic earnings per share was 0.0262 yuan.
Berry Genomics (000710.SZ): Board of Directors Secretary Ai Wenlu has resigned.
On July 24th, Gelonhui reported that Berry Genomics (000710.SZ) announced that the board of directors of the company recently received the resignation report of Ms. Aiwenlu, the secretary of the board of directors of the company. Ms. Aiwenlu resigned from the secretary of the board of directors due to job adjustment and will serve in other positions in the company after her resignation. As of the date of this announcement, Ms. Aiwenlu did not directly hold any shares of the company. To ensure the orderly operation of the board of directors, the ninth meeting of the tenth board of directors of the company reviewed and passed the resolution on appointing the secretary of the board of directors of the company, agreeing that Mr. Xu Fei, the director of investor relations of the company, will serve as the secretary of the board of directors of the company and perform the duties of the secretary of the board of directors.
Berry Genomics: 2024 Interim Performance Forecast
No Data
No Data